DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Barrett's esophagus — screening already-approved drugs against its 35-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBarrett's esophagus maps to a 35-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for barrett's esophagus is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
T-box transcription factor 5 (TBX5) — TBX5 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2-{2-[2-(2-ethoxy-ethoxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2X6U · 1.9 Å · ligand 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL (PE4). Experimental structure, not a prediction.
What the evidence adds up to
Barrett’s esophagus is defined by the presence of intestinal metaplasia in the oesophagus, and cardiac mucosa is its precursor; both arise from gastroesophageal reflux. Intestinal metaplasia, even short segments, is considered premalignant, and the presence of dysplasia signals progression toward adenocarcinoma. A 2017 observational study of 500 outpatients found an overall Barrett’s prevalence of 1.8%, with a mean age of 58.7 years and 66% male predominance. In the 125 patients with reflux symptoms, prevalence rose to 7.2%. Independent associations were gastroesophageal reflux and hiatal hernia.
p53 immunostaining has been investigated as a risk marker. In 41 patients with Barrett’s and sequential histology, the percentage of p53-positive samples correlated with the severity of dysplasia. Among those with indefinite dysplasia, a statistically significant difference in p53 positivity was seen between patients who later progressed to more severe dysplasia and those who did not. The authors described the technique as simple, economical, and quick, and suggested it could aid follow-up.
Treatment options remain contested. Antireflux surgery, unlike medical therapy, may induce regression or halt progression of intestinal metaplasia. High-grade dysplasia is frequently associated with an unrecognised adenocarcinoma focus; vagal-sparing oesophagectomy can be curative at that stage. Once invasion extends beyond the mucosa, lymph node metastases become likely and lymphadenectomy is required. A 2016 review of recent clinical trials noted that new data have cast doubt on older diagnostic and management recommendations, and that persisting controversies remain despite updated guidelines and consensus statements.
What is still missing are prospective trials that stratify patients by molecular markers such as p53 status, and adequately powered studies comparing surgical and medical management with long-term adenocarcinoma incidence as the endpoint. The cost and logistics of endoscopic surveillance programmes in unselected populations also remain unresolved.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Surgery · 2000 · 271 citations · open access
Columnar Mucosa and Intestinal Metaplasia of the Esophagus
AbstractOBJECTIVE: To outline current concepts regarding etiology, diagnosis, and treatment of intestinal metaplasia of the esophagus and cardia. SUMMARY BACKGROUND DATA: Previously, endoscopic visualization of columnar mucosa extending a minimum of 3 cm into the esophagus was sufficient for the diagnosis of Barrett's esophagus, but subsequently the importance of intestinal metaplasia and the premalignant nature of Barrett's have been recognized. It is now apparent that shorter lengths of intestinal metaplasia are common, and share many features of traditional 3-cm Barrett's esophagus. METHODS: Themes and concepts pertaining to intestinal metaplasia of the esophagus and cardia are developed based on a review of the literature published between 1950 and 1999. RESULTS: Cardiac mucosa is the precursor of intestinal metaplasia of the esophagus. Both develop as a consequence of gastroesophageal reflux. Intestinal metaplasia, even a short length, is premalignant, and the presence of dysplasia indicates progression on the pathway to adenocarcinoma. Antireflux surgery, as opposed to medical therapy, may induce regression or halt progression of intestinal metaplasia. The presence of high-grade dysplasia is frequently associated with an unrecognized focus of adenocarcinoma. Vagal-sparing esophagectomy removes the diseased esophagus and is curative in patients with high-grade dysplasia. Invasion beyond the mucosa is associated with a high likelihood of lymph node metastases and requires lymphadenectomy. CONCLUSIONS: Despite improved understanding of this disease, controversy about the definition and best treatment of Barrett's esophagus continues, but new molecular insights, coupled with careful patient follow-up, should further enhance knowledge of this disease.
Immunohistochemical detection of p53 protein could improve the management of some patients with Barrett esophagus and mild histologic alterations.
AbstractOBJECTIVE: To determine the usefulness of p53 immunostaining in identifying the subgroup of patients with Barrett esophagus who may be at increased risk of developing adenocarcinoma of the esophagus. MATERIALS AND METHODS: Tissue samples of 41 patients with Barrett esophagus and available sequential histologic data were processed for p53 immunostaining. Results from each patient were compared over time, and the results of a subset of patients were compared with each other. RESULTS: We observed a significant correlation between the percentage of samples with p53 expression and the severity of dysplasia. Moreover, in a subset of patients with mild dysplasia (cases classified as showing indefinite dysplasia), we observed a statistically significant difference in the percentage of p53-positive samples between the group that progressed to more severe dysplasia and the group that did not progress. CONCLUSION: Our results suggest that this procedure, which is technically simple, economical, and quick, could play a role in the evaluation and follow-up of patients with Barrett esophagus.
Revista de Gastroenterología de México · 2017 · 8 citations · open access
Prevalencia de esófago de Barrett: estudio observacional en una clínica de gastroenterología
AbstractEl esófago de Barrett es una condición que predispone al adenocarcinoma esofágico. Nuestro objetivo fue establecer la prevalencia de esófago de Barrett en nuestro centro, así como los factores asociados a esta condición. Evaluamos retrospectivamente los reportes de 500 endoscopias superiores de pacientes ambulatorios de nuestro Servicio de Gastroenterología entre noviembre del 2014 y abril del 2016. Se determinó la prevalencia de esófago de Barrett y se analizaron los datos demográficos, clínicos y endoscópicos asociados a esta patología. La prevalencia de esófago de Barrett fue del 1.8%. La edad media en los pacientes con esófago de Barrett fue de 58.7 años (rango: 45-70), con predominancia del sexo masculino (66%). En el subgrupo de pacientes con síntomas de reflujo gastroesofágico (n = 125) la prevalencia de esófago de Barrett fue del 7.2%. En el análisis multivariado los factores asociados a esófago de Barrett de forma independiente fueron: síntomas de reflujo gastroesofágico (p = 0.005) y hernia hiatal (p = 0.006). La prevalencia global de esófago de Barrett es del 1.8% en nuestra población, con una prevalencia del 7.2% en pacientes con síntomas de reflujo gastroesofágico. Barrett's esophagus is a condition that predisposes to esophageal adenocarcinoma. Our aim was to establish the prevalence of Barrett's esophagus at our center, as well as determine its associated factors. We retrospectively assessed the endoscopic reports of 500 outpatients seen at our Gastroenterology Service from November 2014 to April 2016. We determined the prevalence of Barrett's esophagus and analyzed the demographic, clinical, and endoscopic findings associated with that pathology. The prevalence of Barrett's esophagus was 1.8%. The mean age of the patients with Barrett's esophagus was 58.7 years (range: 45-70) and there was a predominance of men (66%). In the subgroup of patients with symptoms of gastroesophageal reflux (n = 125), Barrett's esophagus prevalence was 7.2%. In the multivariate analysis, the factors that were independently associated with Barrett's esophagus were gastroesophageal reflux (P=.005) and hiatal hernia (P=.006). The overall prevalence of Barrett's esophagus was 1.8% in our population, with a prevalence of 7.2% in patients that had symptoms of gastroesophageal reflux.
Annals of Gastroenterology · 2016 · 3 citations · open access
Barrett’s esophagus: lessons from recent clinical trials
AbstractData from recent studies cast doubt on former recommendations on diagnosis and management of Barrett's esophagus. Based on latest research findings several Gastroenterological Associations actualized their guidelines and international experts compiled consensus statements as practical help for clinicians. In this review we discuss recent trials and their impact on clinical practice, current recommendations and persisting controversies in Barrett's esophagus.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
